» Articles » PMID: 31369163

Radiolabeled IgG Antibodies: Impact of Various Labels on Neonatal Fc Receptor Binding

Overview
Date 2019 Aug 2
PMID 31369163
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The number of therapeutic antibodies in research and development as well as their complexity increases from year to year. Novel therapeutic protein formats, such as Fc-fusions, bispecific, or multivalent antibodies, are currently in preclinical and clinical development. Therefore, the need for biodistribution and imaging studies, eg, with radiolabeled proteins are very high. However, the labeling process or the label itself can have an impact on binding to cellular receptors, eg, to neonatal Fc receptor (FcRn), which can lead to altered PK properties compared with the unlabeled antibody. FcRn affinity chromatography allows the assessment of immunoglobulin G (IgG) samples with respect to their pH-dependent FcRn interaction. We analyzed IgGs with different types of labels, namely, direct iodination with I; chelating agents, such as DOTA and DOTAM; and [ H]propionate. Direct radio-iodination leads to shifts in FcRn column retention time, which might indicate a potentially faster clearance. Furthermore, high conjugation ratios of chelator lower the affinity to FcRn successively and thus may influence the lysosomal degradation of the antibody in endothelial cells. In contrast, IgGs labeled with [ H]propionate did not show any timeshifts in FcRn affinity chromatography. This article is based on the oral presentation at the IIS 2018 Prague and highlights the importance of an affinity chromatography for characterization of potential changes in affinity to FcRn itself or charge and hydrophobicity.

Citing Articles

Tritium Labeling of Neuromedin S by Conjugation with [H]-Succinimidyl Propionate.

Edelmann M, Erny J, Guba W, Hierl M ACS Omega. 2023; 8(2):2367-2376.

PMID: 36687043 PMC: 9851027. DOI: 10.1021/acsomega.2c06758.


Radiolabelling small and biomolecules for tracking and monitoring.

Edelmann M RSC Adv. 2022; 12(50):32383-32400.

PMID: 36425706 PMC: 9650631. DOI: 10.1039/d2ra06236d.


Deciphering albumin-directed drug delivery by imaging.

Hu H, Quintana J, Weissleder R, Parangi S, Miller M Adv Drug Deliv Rev. 2022; 185:114237.

PMID: 35364124 PMC: 9117484. DOI: 10.1016/j.addr.2022.114237.


Functional in vitro assessment of modified antibodies: Impact of label on protein properties.

Edelmann M, Hauri S PLoS One. 2021; 16(9):e0257342.

PMID: 34529712 PMC: 8445452. DOI: 10.1371/journal.pone.0257342.


A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.

Timmermand O, Orbom A, Altai M, Zedan W, Holmqvist B, Safi M Cancers (Basel). 2021; 13(14).

PMID: 34298682 PMC: 8307315. DOI: 10.3390/cancers13143469.